Literature DB >> 22710971

Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer.

Meltem Ozlen Dillioglugil1, Haluk Mekık, Bahar Muezzinoglu, T Alp Ozkan, Cennet Gural Demir, Ozdal Dillioglugil.   

Abstract

OBJECTIVES: Our objective was to examine blood and tissue levels of nitric oxide (NO) and malondialdehyde (MDA), and their correlations with well-known prognostic indicators [total prostate-specific antigen (tPSA), %free/total PSA (%f/t PSA), pathological stage (pT), and Gleason sum] in patients who had radical retropubic prostatectomy (RRP) for localized prostate cancer (PCa) without metastasis. PATIENTS AND METHODS: Preoperatively 31 patients' bloods were obtained for determination of NO, MDA, fPSA, tPSA, and %f/tPSA ratios. Tissues were obtained from RRP specimens for determination of NO and MDA. Gleason sum was assigned for each patient, and pT was determined according to 2002 TNM staging system. pTs were as follows: 10 pT2a, 7 pT2b, 8 pT2c, 4 pT3a, and 2 pT3b. Gleason sum of the PCa in the RRP specimens was as follows: 5 in 1, 6 in 14, 7 in 14, and 9 in 2 patients.
RESULTS: There were strong correlations between blood and tissue levels of NO (r=0.83, p<0.001) and MDA (r=0.63, p<0.001), between serum NO and plasma MDA (r=0.88, p<0.001), and finally between tissue NO and tissue MDA (r=0.83, p<0.001). There was also a significant (p<0.05) relationship between all well-known prognostic indicators of PCa (tPSA, %f/tPSA, Gleason sum, and pT) and blood and tissue NO and MDA levels, with single exception of correlation between tissue MDA and Gleason sum (p=0.073).
CONCLUSION: Clinically appropriate correlations shown in this study indicates that NO and MDA may be used for prognostic assessment of localized PCa, especially if supported with other well-designed studies including higher number of patients through multi-institutional collaboration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710971     DOI: 10.1007/s11255-012-0221-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

Review 1.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

Authors:  Barry Halliwell; Matthew Whiteman
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

2.  Selective expression of inducible nitric oxide synthase in human prostate carcinoma.

Authors:  T Klotz; W Bloch; C Volberg; U Engelmann; K Addicks
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

3.  Effect of clopidogrel on nitric oxide levels in an ischemia reperfusion model.

Authors:  Muhip Kanko; Meltem Ozden; Hale Maral; Cigdem Acil
Journal:  J Cardiovasc Pharmacol       Date:  2006-07       Impact factor: 3.105

4.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 5.  The pathophysiological significance of lipid peroxidation in oxidative cell injury.

Authors:  D L Tribble; T Y Aw; D P Jones
Journal:  Hepatology       Date:  1987 Mar-Apr       Impact factor: 17.425

6.  Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method.

Authors:  N K Cortas; N W Wakid
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

Review 7.  Can antioxidant vitamins materially reduce oxidative damage in humans?

Authors:  M R McCall; B Frei
Journal:  Free Radic Biol Med       Date:  1999-04       Impact factor: 7.376

8.  Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma.

Authors:  S Baltaci; D Orhan; C Gögüs; K Türkölmez; O Tulunay ; O Gögüs
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

9.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

Authors:  Simona Nanni; Valentina Benvenuti; Annalisa Grasselli; Carmen Priolo; Aurora Aiello; Stefania Mattiussi; Claudia Colussi; Vittoria Lirangi; Barbara Illi; Manuela D'Eletto; Anna Maria Cianciulli; Michele Gallucci; Piero De Carli; Steno Sentinelli; Marcella Mottolese; Paolo Carlini; Lidia Strigari; Stephen Finn; Elke Mueller; Giorgio Arcangeli; Carlo Gaetano; Maurizio C Capogrossi; Raffaele Perrone Donnorso; Silvia Bacchetti; Ada Sacchi; Alfredo Pontecorvi; Massimo Loda; Antonella Farsetti
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

Review 10.  The multifaceted roles of nitric oxide in cancer.

Authors:  D A Wink; Y Vodovotz; J Laval; F Laval; M W Dewhirst; J B Mitchell
Journal:  Carcinogenesis       Date:  1998-05       Impact factor: 4.944

View more
  6 in total

Review 1.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

2.  Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies.

Authors:  Cheng Zhao; Weiqian Yan; Xiongbing Zu; Minfeng Chen; Longfei Liu; Shushan Zhao; Hong Liu; Xia Hu; Renna Luo; Yang Xia; Lin Qi
Journal:  Tumour Biol       Date:  2014-11-06

Review 3.  Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Authors:  Vincenzo Quagliariello; Sabrina Rossetti; Carla Cavaliere; Rossella Di Palo; Elvira Lamantia; Luigi Castaldo; Flavia Nocerino; Gianluca Ametrano; Francesca Cappuccio; Gabriella Malzone; Micaela Montanari; Daniela Vanacore; Francesco Jacopo Romano; Raffaele Piscitelli; Gelsomina Iovane; Maria Filomena Pepe; Massimiliano Berretta; Carmine D'Aniello; Sisto Perdonà; Paolo Muto; Gerardo Botti; Gennaro Ciliberto; Bianca Maria Veneziani; Francesco De Falco; Piera Maiolino; Michele Caraglia; Maurizio Montella; Rosario Vincenzo Iaffaioli; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-05-02

Review 4.  Predicting disease onset in clinically healthy people.

Authors:  Harold I Zeliger
Journal:  Interdiscip Toxicol       Date:  2017-05-17

Review 5.  Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.

Authors:  Margarita Neganova; Junqi Liu; Yulia Aleksandrova; Sergey Klochkov; Ruitai Fan
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 6.  Evidence in support of potential applications of lipid peroxidation products in cancer treatment.

Authors:  Omotayo O Erejuwa; Siti A Sulaiman; Mohd S Ab Wahab
Journal:  Oxid Med Cell Longev       Date:  2013-12-04       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.